Mission Statement, Vision, & Core Values (2026) of Jointown Pharmaceutical Group Co., Ltd.

From its founding as Swan Pharmaceutical Wholesale in 1985 to becoming China's largest non-state-owned medical company by revenue, Jointown Pharmaceutical Group has grown into a global healthcare powerhouse distributing over 510,000 medical and pharmaceutical products through a logistics footprint exceeding 44 million square feet of warehouse space and more than 400 subsidiaries, with international hubs in Los Angeles, New York, Frankfurt and Melbourne and reported 2022 revenue of about US$19.8 billion (ranked 93rd on the Fortune 500 China list); this chapter peels back the strategy behind Jointown's mission to deliver accessible, affordable and high-quality healthcare, its vision to become a leading intelligent and service-driven manufacturer and platform, and the core values-integrity, innovation, customer-centricity, collaboration, responsibility and tolerance-that steer its R&D, supply-chain upgrades and global expansion, inviting you to explore how these concrete figures shape strategy and impact real-world healthcare delivery

Jointown Pharmaceutical Group Co., Ltd (600998.SS) - Intro

• Established: 1985 (originally Swan Pharmaceutical Wholesale)
• 2022 Revenue: ~US$19.8 billion
• Fortune 500 China Rank (2022): 93rd
• Product portfolio: >510,000 SKUs (pharmaceuticals, devices, consumables)
• Warehouse footprint: >44 million sq ft of medical storage capacity
• Subsidiaries: 400+ across China and abroad
• Global presence: Offices and warehouses in Los Angeles and New York; operations in Frankfurt and Melbourne

• Provide accessible, affordable, and high-quality healthcare products across China and select global markets.
• Continuously innovate in pharmaceutical research, development, and distribution to improve patient outcomes.
• Operate sustainably and responsibly to create long-term value for communities, partners, and stakeholders.

• Be the trusted global healthcare supply-chain partner, integrating distribution, logistics, and clinical solutions to enhance healthcare accessibility and resilience.
• Leverage scale, technology, and partnerships to expand international footprint while preserving affordability and quality.

• Patient-first: prioritize safety, efficacy, and access in every decision.
• Integrity: maintain transparent, compliant commercial and operational practices.
• Innovation: invest in R&D, digitalization, and logistics optimization to drive efficiency and new service models.
• Collaboration: build long-term partnerships across manufacturers, healthcare providers, and governments.
• Sustainability: balance growth with environmental stewardship and community health responsibilities.

Jointown Pharmaceutical Group Co., Ltd (600998.SS) - Overview

• Provide accessible, affordable, high-quality healthcare products across urban and rural China.
• Continuously innovate in pharmaceutical research, product sourcing, and digital health solutions.
• Operate sustainably with attention to community contributions and environmental responsibilities.
• Adhere to ethical practices and transparency in procurement, distribution, and corporate governance.
• Enhance population health and quality of life by expanding integrated service coverage.
• Build and scale a comprehensive healthcare service platform integrating distribution, retail, logistics, and online services.

• Accessibility: expanding service footprint to reach underserved regions via logistics and retail networks.
• Affordability: optimizing procurement and supply-chain efficiencies to reduce end-user costs.
• Quality: enforcing GMP-compliant sourcing, cold-chain management for temperature-sensitive products, and stringent supplier vetting.
• Innovation: deploying digital platforms, e-commerce channels, and data-driven supply-chain optimization.
• Sustainability & community: implementing environmentally conscious warehousing, packaging initiatives, and local healthcare outreach programs.
• Ethics & transparency: public disclosures, regulatory compliance, and anti-corruption controls across operations.

• Platform integration: combining distribution, retail, and digital services to create end-to-end healthcare solutions.
• Supply-chain resiliency: investing in logistics, cold chain, and regional hubs to ensure uninterrupted supply.
• Digital transformation: expanding e-commerce, B2B platforms, telemedicine integration, and data analytics for operations and patient services.
• R&D and product sourcing: partnerships and selective development to broaden therapeutic coverage and product affordability.
• ESG and governance: strengthening environmental initiatives, social responsibility programs, and transparent governance practices.

• Customer first - patient and institutional needs drive service design and quality standards.
• Integrity - compliance, transparency, and ethical conduct across procurement and distribution.
• Innovation - continuous improvement using technology and process enhancements.
• Collaboration - partnerships with manufacturers, hospitals, pharmacies, and communities.
• Responsibility - sustainable operations and community health contributions.

Jointown Pharmaceutical Group Co., Ltd (600998.SS) - Mission Statement

• Deliver safe, effective pharmaceuticals and health services to hospitals, clinics, pharmacies and consumers.
• Build an integrated supply chain that lowers costs, shortens lead times and improves availability of essential medicines.
• Leverage technology to create an intelligent, data-driven healthcare service platform.
• Foster research, innovation and product development to expand into higher-value therapeutic and beauty segments.
• Expand domestic and overseas market reach while maintaining strong regulatory compliance and quality control.

• Integrated Supply Chain - national warehousing network, logistics capabilities and wholesale distribution to enable scale and resilience.
• Manufacturing & Brand Medicines - upgrade production facilities, apply GMP/ICH standards and build leading in-house brands.
• Digital Transformation - ERP, intelligent warehousing, big data and AI for demand forecasting, procurement and customer service.
• Omnichannel Retail - growth of pharmacy retail outlets and e-commerce channels to reach end consumers directly.
• R&D & New Business Development - investment into new therapeutic areas and beauty/consumer health products.

• Become a respected manufacturer with leading brand medicines and a service provider in the healthcare field with industry reputation.
• Build the most professional comprehensive health service platform in China, integrating manufacturing, distribution, retail and digital services.
• Transform into a fully intelligent enterprise by embracing advanced technologies - AI-driven forecasting, automated warehousing and cloud-based operations.
• Expand customer base and market coverage across more domestic provinces and targeted overseas regions in Southeast Asia and beyond.
• Upgrade production and management systems, introduce new technologies to increase added value across the supply chain.
• Position Jointown as a leader in the complete beauty industry while capturing growth opportunities from R&D-driven new businesses.

Jointown Pharmaceutical Group Co., Ltd (600998.SS) Vision Statement

• Integrity - Uphold ethical conduct, regulatory compliance, and transparent reporting across procurement, distribution, and corporate governance.
• Innovation - Invest in digital supply-chain technologies, cold-chain logistics, and R&D partnerships to accelerate new product delivery and operational efficiency.
• Customer-Centricity - Prioritize end-to-end value for hospitals, pharmacies, and institutional clients through tailor-made logistics, information services, and after-sales support.
• Collaboration - Foster strategic alliances with manufacturers, research institutes, and international distributors to co-develop products and expand geographical reach.
• Responsibility - Commit to social responsibility programs, equitable access to medicines, environmental stewardship, and workplace safety across operations.
• Tolerance - Promote diversity of thought, inclusive workplace policies, and adaptability to evolving market and regulatory environments.

• Strengthen national and cross-border distribution networks to reduce delivery lead times and stockouts.
• Scale digital platforms for inventory visibility and demand forecasting to lower working capital intensity.
• Expand value-added services (clinical support, chronic disease management, product training) to deepen customer relationships.
• Increase investment in cold-chain capacity and biologics handling to capture higher-margin segments.

• Integrity: Adoption of enhanced compliance dashboards and quarterly internal audits; supplier due-diligence coverage increased to >95% of procurement spend.
• Innovation: Rollout of AI-driven demand forecasting reduced stockout incidents by a reported mid-single-digit percentage in pilot regions.
• Customer-Centricity: Net Promoter Score (NPS) and institutional retention targets embedded in regional KPIs; service-level agreements tightened to sub-24-hour fulfillment in tier-1 cities.
• Collaboration: Strategic partnerships with domestic manufacturers and a growing roster of international supplier agreements to broaden therapeutic portfolios.
• Responsibility: Community health programs and donations during public-health emergencies represent multi-million RMB contributions annually.
• Tolerance: Recruitment and leadership programs emphasize cross-functional mobility and representation across 10+ provinces.

• Integrated logistics hubs combining warehousing, cold-chain, and real-time tracking to lower lead times and shrinkage.
• Digital platform investments connecting suppliers, distributors, and customers for transparency and faster settlements.
• Capability-building for specialty product handling (biologics, medical devices) to access higher-margin channels.